Document:

Exhibit 10.53

 

EMPLOYMENT AGREEMENT

 

THIS EMPLOYMENT AGREEMENT
(“Agreement”) is made and shall be effective as of November 11, 2013 (the “Effective Date”),
by and between CAPRICOR, INC., a Delaware corporation, whose offices are located at 8840 Wilshire Blvd., 2nd Floor, Beverly
Hills, California 90211 and/or any successor entity thereto (the “Company”), and ANDREW HAMER, M.D. (“Employee”)
who currently resides at 48B Bronte Street, Nelson, New Zealand 7010.

 

A.          The Company desires
to assure itself of the services of Employee by engaging Employee to perform services under the terms hereof;

 

B.          Employee desires to provide services
to the Company on the terms herein provided; and

 

C.          The
parties now desire to enter into a definitive agreement which shall set forth the full terms and conditions of Employee’s
employment.

 

NOW, THEREFORE, in consideration
of the mutual covenants, promises, and agreements set forth herein and for good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereby mutually agree as follows:

 

1.           EMPLOYMENT. The Company
hereby agrees to employ Employee, and Employee hereby agrees to accept employment with the Company, upon the terms and conditions
herein set forth. The Effective Date and commencement of this Agreement is conditioned upon and subject to Employee obtaining all
necessary documentation and authorization to enable Employee to immigrate to and work in the United States. If such authorization
is not secured prior to the Effective Date set forth above, the Effective Date shall be modified subject to the provisions of Section
7.1 below.

 

2.          DUTIES
AND POWERS OF EMPLOYEE

 

2.1          Duties of Employee.
Employee shall serve as the Vice President of Medical Affairs of the Company reporting directly to the Chief Executive Officer
or to such other person designated by the Chief Executive Officer. In that capacity, Employee shall do and perform all services,
acts or things necessary or advisable to develop, supervise and oversee the clinical operations of the Company (collectively,
the “Services”). Employee’s responsibilities shall include, without limitation, performing those Services
set forth on Exhibit A, attached hereto and incorporated herein, which may be amended from time at the discretion
of the Company. During the duration of his employment, and except for periods of illness, vacation, or reasonable leaves of absence,
Employee shall devote his full time and attention to the business and affairs of the Company, as such business and affairs now
exist and as they hereafter may be changed or added to, under and pursuant to the general direction of the Company’s Board
of Directors (the “Board”).

 

    	1

    	 

    

 

2.2          Place of Performance.
Employee shall perform his duties from the Company’s offices located in Beverly Hills, California unless otherwise directed
by the Company or otherwise specifically authorized in writing or required in the performance of his duties. The Company agrees
not to relocate the Employee to any location more than 50 miles away from Beverly Hills. If such relocation becomes necessary,
Employee shall have the right to terminate this Agreement. Notwithstanding the foregoing, any such relocation will not be considered
a breach of this Agreement by the Company. The parties acknowledge that Employee is currently residing in New Zealand and that
it will be necessary for him to relocate to Los Angeles to perform his responsibilities. Employee agrees to complete his relocation
to Los Angeles prior to the Effective Date of this Agreement.  

 

2.3          Other Activities.
During the continuation of his employment hereunder, Employee shall not provide any work or services to any other person or organization
without the prior written consent of the Chief Executive Officer, which consent may be withheld in the Chief Executive Officer’s
sole and absolute discretion. Nothing contained herein shall prohibit Employee from making passive personal investments in publicly
traded companies so long as Employee’s investment does not constitute an equity position greater than five percent (5%)
of such company’s outstanding securities. Notwithstanding the foregoing or anything to the contrary in this Agreement, if
Employee desires to continue consulting for any organization or entity with whom the Employee is currently working, the Company
will not object thereto, provided that (1) such consulting services rendered by Employee are minimal and do not interfere with
the performance of Employee’s responsibilities to the Company, and (2) the business of such organization or entity does
not pose an actual or potential conflict of interest and is not competitive, directly or indirectly, with the business of the
Company. A list of the entities or organizations with whom Employee is currently consulting is attached hereto as Exhibit B.
Such Exhibit B shall be updated regularly by Employee. If Capricor determines that the conditions set for in
subsection (1) or (2) above, are not satisfied, Capricor may terminate this Agreement in accordance with Section 7.2 below.

 

2.4          Company Policies.
By execution of this Agreement, Employee is agreeing to comply with all Company policies, procedures and standards of conduct that
are currently in effect or that may be established by the Company from time to time.

 

3.          COMPENSATION

 

3.1          Base Salary.
In consideration of the Services to be provided by Employee during his employment hereunder, Employee shall receive a base salary
of two hundred twenty five thousand dollars ($225,000) per annum (the “Base Salary”), which sum shall be payable
in semi-monthly installments consistent with Company pay practices. Any increase in Employee’s Base Salary shall be subject
to the sole discretion of the Company’s compensation committee.

 

    	2

    	 

    

  

3.2          Annual
Bonus. In addition to the Base Salary, Employee shall be considered for an annual bonus, the awarding and amount of which
will be in the sole discretion of Capricor’s Board of Directors and dependent upon successful
completion of performance-based milestones to be determined by the Board of Directors and the Employee.

 

3.3          Grant of Stock
Options. As further consideration for the Services to be provided by Employee hereunder, Employee shall be granted a stock
option under the Company’s 2012 Restated Equity Incentive Plan (the “Stock Plan”) to purchase an aggregate
of 45,622 shares of the Company’s Common Stock (the “Option Shares”). The Option Shares shall vest at
the rate of twenty-five percent (25%) per year over a four-year period commencing on the first anniversary of the date which is
the first day of the month following the date of grant and continuing at the rate of twenty-five percent (25%) on each of the three
(3) anniversary dates thereafter. The exercise price for the Option Shares shall be not less than the fair market value of the
shares on the Grant Date as determined by the Company’s Board. The Option Shares shall be further subject to the provisions
of the Stock Plan and the applicable Stock Option Agreement to be executed by the Company and Employee.

 

In the event the Company
consummates a Merger with Nile Therapeutics, Inc. (“Nile”), a publically traded company, the number of options
to be granted to Employee shall be adjusted on the same terms applicable to other Capricor option holders as required by the terms
of the Nile Merger Agreement. Additionally, upon consummation of the merger, the name of Nile Therapeutics shall be changed to
Capricor Therapeutics, Inc. and any options granted post-merger will be issued by Capricor Therapeutics and will enable Employee
to acquire shares in that entity similar to the other Capricor option holders. The grant would be subject to the terms and conditions
of the Stock Option Plan or Equity Incentive Plan then in effect and the specific Stock Option Agreement entered into between Employee
and Capricor Therapeutics or Capricor, Inc., whichever is then applicable. If the merger is not consummated, then any stock options
granted would be issued by the Company and would entitle Employee to purchase Common Stock of the Company. Notwithstanding anything
to the contrary herein or in the Stock Plan, in the event of any merger with Nile Therapeutics, Inc., Employee shall not be treated
any worse than any other holder of stock options or vested shares granted under the Company’s Stock Option Plan.

 

After completion of Employee’s
first year of employment, the Board of Directors may, in its sole discretion, determine whether additional options shall be granted
to Employee considering, among other things, the successful performance of Employee’s obligations hereunder, provided, however,
that nothing herein shall be construed to create an obligation on the part of the Company to grant any additional stock options.

 

    	3

    	 

    

 

3.4          Deduction
of Taxes. The Company shall have the right to deduct or withhold from the compensation due to Employee hereunder any and
all sums required for Federal Income and Social Security taxes and all other federal, state or local taxes now applicable or that
may be enacted and become applicable in the future.

 

4.          OTHER
BENEFITS

 

4.1        Insurance.
Commencing on the first day of the month following the thirty (30)-day period after the Effective Date of this Agreement, and so
long as Employee remains employed by the Company, Employee shall be entitled to participate in the medical, dental and vision insurance
plan which is from time to time made available to other employees of the Company in accordance with the Company’s policy
then in effect. The right to receive such insurance benefits shall vest if and only if any of the foregoing types of insurance
plans are adopted and maintained by the Company. In addition, commencing on the second year of Employee’s employment, the
sum of one thousand dollars ($1,000) shall be deposited into a flexible spending account earmarked for Employee’s benefit
to be used only for qualified medical expenses. If Employee’s employment is terminated for whatever reason before such sum
is expended by him, any remaining balance will be cancelled upon termination of employment.

 

4.2         Vacation
and Personal Leave.

 

(a)          Vacation.
Employee shall be entitled to a maximum of fifteen (15) working days’ vacation time during each one-year period of this Agreement
without loss of compensation, to be taken at a time or times mutually agreed upon by the Company and Employee. Vacation days may
be taken only at such times as are mutually convenient for the Company and Employee. If Employee is unable for any reason to take
the total amount of authorized vacation time for any year, Employee may accrue no more than five (5) days of that time and add
it to vacation time for any following year or alternatively, may receive a cash payment in an amount equal to the amount of annual
salary attributable to that period. Once the maximum accrual has been reached, all further accruals will cease. Vacation accruals
will recommence after Employee has taken his vacation and his accrued hours have dropped below the maximum or Employee has received
pay in lieu of the vacation time.

 

(b)          Personal
Days. Employee shall be entitled to a maximum of four (4) working days’ personal leave (including sick days) during
each one-year period of this Agreement without loss of compensation.

 

    	4

    	 

    

  

4.3           Business
Expenses. The Company shall reimburse Employee monthly for all reasonable business expenses incurred by Employee in performing
the Services hereunder, including, without limitation: (a) expenses incurred for pre-approved business travel; (b) reasonable meals,
lodging, and ground transportation expenses incurred during business travel in accordance with the Company’s travel policy;
(c) pre-approved promotional expenses; (d) long distance telephone charges; and (e) any other expenses which the Company determines
is necessary in connection with the performance of Employee’s Services hereunder. Each such expense shall be reimbursable
only if it is of such a nature qualifying it as a proper deduction on the federal and state income tax returns of the Company.
Employee shall furnish to the Company adequate records, receipts and other documentary evidence required by federal and state statutes
and regulations issued by the appropriate taxing authorities for the substantiation of that expenditure as an income tax deduction.

 

4.4           Sarbanes-Oxley
Act of 2002. Notwithstanding anything herein to the contrary, if the Company determines, in its good faith judgment, that
any provision of this Agreement is likely to be interpreted as a personal loan prohibited by the Sarbanes-Oxley Act of 2002 and
the rules and regulations promulgated thereunder (the “Act”), then such provision shall be modified as necessary
or appropriate so as to not violate the Act and if this cannot be accomplished, then the Company shall use its reasonable efforts
to provide Employee with similar, but lawful, substitute benefits at a cost to the Company not to significantly exceed the amount
the Company would have otherwise paid to provide such benefit(s) to Employee.

 

5.          
OBLIGATIONS OF EMPLOYEE

 

5.1           Confidential
and Proprietary Information. Employee acknowledges and agrees that he has been given, and during the continuance of this
Agreement and in the course of discharging his duties hereunder he will have access to and become acquainted with, information
and know-how concerning the operation, products and processes of the Company which are confidential and/or proprietary to the Company
(and/or its licensors and affiliates). As a condition of Employee’s employment, Employee agrees to execute an At-Will
Employment, Confidential Information, and Invention Assignment Agreement (the “Proprietary Rights Agreement”)
which, among other things, shall set forth Employee’s obligations with respect to the Company’s confidential and proprietary
information. An executed copy of the Proprietary Rights Agreement shall be attached hereto as Exhibit C and incorporated
herein by reference.

 

5.2           Non-Competition
and Non-Solicitation By Employee. Employee acknowledges and agrees that his duty of loyalty to the Company is of paramount
importance.  As a condition of Employee’s employment, Employee acknowledges and agrees to abide by the provisions
regarding non-competition and non-solicitation set forth in the Proprietary Rights Agreement attached hereto as Exhibit C.

 

5.3           Equitable
Remedies. In the event of a breach or threatened breach of the provisions of Section 5 of this Agreement, including its
subsections, the Company shall be entitled to seek an injunction enjoining Employee from such breach, but nothing herein shall
be construed as prohibiting the Company from pursuing in addition any other remedies available for such breach or threatened breach.

 

    	5

    	 

    

  

6.          COMPLIANCE
AND REPRESENTATIONS; ETHICAL CONDUCT

 

6.1           Ethical
Conduct. It is the policy of Capricor to conduct its business at all times in accordance with the highest standards of
corporate, business and medical ethics. Employee agrees to comply with those standards in all matters relating to the Services
and all other performance under or pursuant to this Agreement.

 

6.2           In
the performance of the Services hereunder, Employee will comply with all applicable laws, rules and regulations of any government
or governmental body or board having jurisdiction and all professional standards and guidelines or any code of conduct which may
be applicable to persons involved in the conduct of clinical trials.

 

6.3           Employee
agrees that he will not, either on his own behalf or on behalf of the Company, make any improper payment or make any donation,
or give anything of value, either directly or indirectly, to an official of any government for the purpose of improperly influencing
an act or decision of the official in his or her official capacity or inducing the official to use his or her influence to assist
Employee or the Company in obtaining or maintaining business or for any other improper purpose prohibited by applicable law or
the public policies of the U.S. or any country in which the Company’s clinical trials are conducted.

 

6.4           Employee
shall not, in the name, on behalf or for the benefit of the Company or any of its affiliates or in respect any clinical trial which
it is conducting, offer, pay, give, promise to pay or give, or authorize the payment or gift of money or anything of value to any
official, political party (or employee of a customer) or to any other person at the request, suggestion or direction of any official,
political party (or employee of a customer) or when all or a portion of such money or thing of value will be offered, given or
promised, directly or indirectly, to any such person for the purpose of improperly obtaining or retaining business or favorable
governmental action.

 

6.5           Employee
represents that as of the time of the signing of this Agreement, he has not been debarred in the conduct of clinical trials and
he will not knowingly use the services of any debarred person in connection with any work on any clinical trial conducted by the
Company. If at any time after execution of this Agreement and continuing for a period of one (1) year after the termination hereof,
Employee becomes aware that he or any person utilized for the conduct of any of the Company’s clinical trials is, or is knowingly
in the process of being debarred, Employee shall so notify the Company in writing immediately.

 

    	6

    	 

    

  

7.          
TERM; TERMINATION OF EMPLOYMENT

 

7.1         Term.
The employment of Employee shall commence on the Effective Date (which date shall be extended until such time when Employee shall
become eligible to work in the U.S.) and shall continue in effect until the third anniversary thereof, unless terminated earlier
by the parties as provided herein. In the event Employee does not receive the requisite clearance to commence work before January
1, 2014, this Agreement shall not become effective and the Company shall have no obligations to Employee hereunder.

 

7.2         Termination.
Notwithstanding any other provision contained in this Agreement, either party shall have the right to terminate this Agreement
at any time after giving the other party at least ten (10) days’ prior written notice with or without cause. In addition,
the Company shall have the right to immediately terminate this Agreement for Cause upon notice to Consultant upon the occurrence
of any Termination Event (as defined below).

 

(a)     For
purposes of this Agreement, the term “Termination Event” shall mean the occurrence of any of the following:

 

		(i)	The commission of an act of fraud or dishonesty by Consultant;

 

		(ii)	The unauthorized use or disclosure of Confidential Information by Consultant;

 

		(iii)	The willful or habitual neglect by Consultant in the performance of the Services;

 

		(iv)	The debarment of Employee or the commencement of debarment proceedings against Employee;

 

		(v)	Consultant is convicted of a felony or other crime involving moral turpitude;

 

		(vi)	Any other conduct by Consultant which is injurious to the business or reputation of Capricor; or

 

		(vii)	Failure of either of the conditions set forth in Section 2.3 (1) or (2) above, and the failure to cure the same within seven
(7) days after notice from the Company.

 

    	7

    	 

    

  

7.3           Payments
Due Upon Termination. Upon termination of Employee’s employment, the Company shall pay to Employee on such date required
by applicable law, a lump sum amount in cash equal to Employee’s Base Salary and other payments due through the Date of Termination
to the extent not theretofore paid. In addition, in the event that the Employee is terminated without Cause during the Term, then
the Company shall pay to Employee a severance payment equal to three (3) months of Employee’s Base Salary then in effect,
provided that Employee execute a general release of all claims requested by the Company.

 

8.          GENERAL
PROVISIONS

 

8.1           Notices.
Any notices to be given by either party to the other may be effected either by personal delivery in writing, by facsimile or electronic
transmission or by mail, registered or certified, postage prepaid. Mailed notices shall be addressed to the parties at the addresses
appearing in the introductory paragraph of this Agreement or such other address on file for Employee in Employee’s personnel
records, but each party may change its address by written notice in accordance with this section. Notices personally delivered
or sent by facsimile transmission shall be deemed communicated as of the date of actual receipt; mailed notices shall be deemed
communicated two (2) days after the date on which they are mailed.

 

8.2           Entire
Agreement. This Agreement supersedes any and all other agreements, either oral or in writing, between the parties with
respect to the employment of Employee by the Company, excluding the Proprietary Rights Agreement, any Award Agreement entered into
pursuant to the 2012 Restated Equity Incentive Plan consistent with paragraph 3.3 above, and a Dispute Resolution and Mutually
Binding Arbitration Agreement to be executed by the parties, and contains all of the covenants and agreements between the parties
with respect to that employment in any manner whatsoever. Each party acknowledges that no representations, inducements, promises,
or agreements, orally or otherwise, other than those set forth herein, have been made by any party, or anyone acting on behalf
of any party, and that no other agreement, statement, or promise between the parties not contained in this Agreement shall be valid
or binding on the parties. Any modification of this Agreement will be effective only if it is in writing and signed by both parties
to this Agreement. If there is any conflict between the terms of the Proprietary Rights Agreement and this Agreement, the terms
of this Agreement shall control.

 

8.3           Severability.
 If any one or more provisions in this Agreement is held by a court of competent jurisdiction to be invalid, void, or unenforceable,
such provision shall be judicially modified accordingly to make such provision enforceable and if not possible to reasonably
do so, such provision shall be deemed excluded from this Agreement. In such case, the balance of this Agreement shall be interpreted
as if such provision were so excluded and shall be enforceable in accordance with its terms.

  

    	8

    	 

    

 

8.4           Waiver.
The failure of either party to insist on strict compliance with any of the terms, covenants, or conditions of this Agreement by
the other party shall not be deemed a waiver of that term, covenant, or condition, nor shall any waiver or relinquishment of any
right or power at any one time or times be deemed a waiver or relinquishment of that right or power for all or any other times.

 

8.5           Governing
Law. This Agreement and each of its provisions shall be governed by and construed in accordance with the laws of the State
of California (without regard to its conflict of law principles), except that the laws of the State of Delaware shall govern all
matters as to the Stock Plan and Stock Option Agreement.

 

8.6           Agreement
Binding. This Agreement shall inure to the benefit of and be binding upon the Company and its affiliates, successors and
assigns. The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to
all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in
the same manner and to the same extent that the Company would be required to perform it as if no such succession had taken place.

 

8.7           Survival.
Notwithstanding any provision of this Agreement to the contrary, the provisions of Sections 5, 6 and 8 (and each of their subsections)
shall survive the expiration or termination of this Agreement as necessary to give full effect to all of the provisions contained
herein.

 

8.8           Headings
and Captions. Section headings and captions used in this Agreement are for reference only and shall not affect the construction
of this Agreement.

 

IN WITNESS WHEREOF, the
parties have caused this Agreement to be executed as of the Effective Date.

 

	Capricor, Inc.	 	Employee:
	 	 	 	 
	By:	/s/ Linda Marban	 	/s/ Andrew Hamer
	 	Linda Marbán	 	Andrew Hamer, M.D.
	 	Chief Executive Officer	 	 

 

    	9

    	 

    

 

EXHIBIT A

 

THE SERVICES

 

The Services to be performed by Employee shall include, without
limitation, the following:

 

		·	supervising and overseeing the clinical operations of the Company which includes clinical trial design and execution;

		·	coordinating and supervising the clinical trials of the Company, including ALLSTAR and future CDC trials as well as other clinical
trials performed by the Company;

		·	preparing clinical protocols and interfacing with the CTEC and CEC;

		·	initiating and screening CROs, consultants and other experts as needed for clinical trial implementation;

		·	supervising and maintaining clinical quality assurance and quality control; and

		·	providing medical leadership regarding new products and indications under investigation by the Company which may include reviewing
clinical data, reviewing relevant animal data, preparation of reports, and reviewing literature. 

 

    	10

    	 

    

 

 

EXHIBIT B

 

EMPLOYEE’S DISCLOSURE OF 

 

OTHER CONSULTING ACTIVITIES 

 

	1.	The Minister of Health in New Zealand
	 	 
	2.	Ministry of Health New Zealand
	 	 
	3.	The National Health Board of New Zealand
	 	 
	4.	The Heart Foundation of New Zealand
	 	 
	5.	 

 

    	11Exhibit 10.54

 

*** Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 C.F.R. §§ 200.80(b)(4)

and 230.406

 

FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT

 

THIS FIRST AMENDMENT TO
EXCLUSIVE LICENSE AGREEMENT (this “Amendment”) is made and entered into as of February 27, 2015 (“Amendment Date”),
by and between CEDARS-SINAI MEDICAL CENTER, a California nonprofit public
benefit corporation (“CSMC”), and CAPRICOR, INC., a Delaware
corporation (“Licensee”), under the following circumstances:

 

		A.	CSMC and Licensee entered into an Exclusive License Agreement
dated May 5, 2014 (the “License Agreement”).

 

		B.	The parties desire to amend the License Agreement as further
described herein.

 

NOW, THEREFORE, in consideration
of the mutual promises and covenants contained herein and in the License Agreement and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

 

1.          Defined
Terms. Terms not otherwise defined herein shall have the meaning ascribed to them in the License Agreement.

 

2.          Amendments
to the License Agreement.

 

(a)          The
following new Section 4.5 is hereby added at the end of Article 4 of the License Agreement:

 

“4.5           Product
Development Milestones. Licensee agrees to pay and shall pay to CSMC the following non-creditable, non-refundable product development
milestone payments within sixty (60) days of the first occurrence of a milestone:

 

	Milestone Event	 	Milestone Payment	 
	Milestone 1: Dosing of first patient in a Phase I clinical trial of a Product	 	$	15,000	 
	Milestone 2: Dosing of first patient in a Phase II clinical trial of a Product	 	$	[...***...]	 
	Milestone 3: Dosing of first patient in a Phase III clinical trial of a Product	 	$	[...***...]	 
	Milestone 4: Submission of NDA or BLA to the FDA for a Product	 	$	[...***...]	 
	Milestone 5: Receipt of U.S. marketing approval of a Product	 	$	75,000	 

 

For the avoidance of doubt,
Licensee shall be only required to pay each of the milestone payments required by this Section 4.5 one time.”

 

*Confidential Treatment Requested

 

    	1

    	 

    

 

(b)          Schedule
A (Patent Rights) to the License Agreement is hereby deleted and replaced in its entirety with Revised Schedule A hereto
for the purpose of adding certain Future Patent Rights (patent applications 3-6 on Revised Schedule A) to the definition of “Patent
Rights”.

 

(c)          Within
thirty (30) days of the Amendment Date, Licensee shall pay to CSMC the following non-refundable amounts:

 

(i)          An
upfront fee in the amount of Twenty Thousand U.S. Dollars ($20,000); and

 

(ii)         The
unreimbursed costs, including attorneys’ fees and filing fees, actually incurred to date by CSMC in the prosecution of patent
applications 3-6 on Revised Schedule A, which amounts to a total of $34,219.04 as of the Amendment Date.

 

3.          Other
Provisions. This Amendment is a revision to the License Agreement only, it is not a novation thereof. Except as otherwise
provided herein, the terms and conditions of the License Agreement shall remain in full force and effect.

 

4.          Further
Assurances. Each of the parties hereto shall execute such further documents and instruments, and do all such further
acts, as may be necessary or required in order to effectuate the intent and accomplish the purposes of this Amendment.

 

5.          Counterparts.
This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which taken
together shall constitute one and the same instrument.

 

IN WITNESS WHEREOF, the parties have executed
this Amendment to Exclusive License Agreement as of the day and year first above written.

 

	Dated:   February 27, 2015	CAPRICOR, INC.
	 	 	 	 
	 	 	By:	/s/ Karen Krasney
	 	 	 	Name: Karen Krasney
	 	 	 	Title: EVP, General Counsel
	 	 	 	 
	Dated:    February 27, 2015	CEDARS-SINAI MEDICAL CENTER
	 	 	 	 
	 	 	By:	 /s/ James D. Laur, Esq.
	 	 	 	Name:	James D. Laur, Esq.
	 	 	 	Title:	Vice President, Legal & Technology Affairs
	 	 	 	 	 
	 	 	By:	/s/ Edward M. Prunchunas
	 	 	 	
        Name: Edward M. Prunchunas

	 	 	 	Title: Sr. V.P., Finance, and CFO

 

    	2

    	 

    

 

REVISED
SCHEDULE A

Patent
Rights

 

1.

[...***...]

 

 

2.

[...***...]

 

 

3.

[...***...]

 

 

4.      

[...***...]

  

 

5.      

[...***...]

 

*Confidential Treatment Requested

 

    	3

    	 

    

 

[...***...]

 

 

6.      

[...***...]

 

*Confidential Treatment Requested

 

    	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]